Prostaglandins & other lipid mediators最新文献

英文中文

IF 2.5 3区生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

Prostaglandins & other lipid mediators

Pub Date : 2025-01-01

引用次数: 0

IF 2.5 3区生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

Prostaglandins & other lipid mediators

Pub Date : 2025-01-01

引用次数: 0

IF 2.5 3区生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

Prostaglandins & other lipid mediators

Pub Date : 2025-01-01

引用次数: 0

IF 2.5 3区生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

Prostaglandins & other lipid mediators

Pub Date : 2025-01-01

引用次数: 0

TFAP2A activates CTHRC1 to influence the migration of lung adenocarcinoma cells by modulating fatty acid metabolism TFAP2A激活CTHRC1，通过调节脂肪酸代谢影响肺腺癌细胞的迁移。

IF 2.5 3区生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

Prostaglandins & other lipid mediators

Pub Date : 2025-01-01 DOI: 10.1016/j.prostaglandins.2024.106941

Xiaodong Zheng , Junzheng Zhou , Shiwei Nie , Yuan Chen , Xudong Wei , Jinrui Zhang , Xiaojuan Shen , Weimin Zhang

Background

Tumor metastasis is the main cause of death in lung adenocarcinoma (LAC) patients. It is known that the collagen triple helix repeats containing 1 (CTHRC1) protein is implicated in tissue remodeling and is tightly linked to the carcinogenesis and metastasis of solid tumors. However, the functional role of CTHRC1 and its potential mechanisms in LAC cell metastasis have not been fully explored.

Methods

The expression level of CTHRC1 in LAC was measured by using bioinformatics analysis combined with quantitative real-time polymerase chain reaction (qRT-PCR) and western blot (WB). Small interfering RNA and overexpression methods were employed to investigate the function and molecular mechanisms of CTHRC1 in LAC cells. Through bioinformatics analysis, qRT-PCR, WB, scratch healing assay, Transwell, assay kits, and flow cytometry, the downstream pathways and upstream regulatory genes of CTHRC1 in LAC cells were investigated. The binding sites were verified by using chromatin immunoprecipitation (ChIP) and dual luciferase reporter gene experiments.

Results

In this project, CTHRC1 was found to be abnormally upregulated in LAC tissues and cells. CTHRC1 promoted the migration and invasion of LAC cells. The promoting effect of CTHRC1 overexpression on LAC cell migration was weakened after the addition of orlistat (a fatty acid synthase inhibitor). Mechanistically, TF AP-2α (TFAP2A) was directly bound to the upstream sequence of the CTHRC1 promoter and promoted CTHRC1 expression. The TFAP2A-CTHRC1 axis induced the migration of LAC cells by activating fatty acid metabolism.

Conclusion

Our results indicated that TFAP2A activates fatty acid metabolism by positively modulating the expression of CTHRC1, thereby facilitating tumor cells’ migration and invasion. These findings provided novel insights into LAC treatment and future research.

背景：肿瘤转移是肺腺癌（LAC）患者死亡的主要原因。已知含有1 （CTHRC1）蛋白的胶原三螺旋重复序列与组织重塑有关，并与实体瘤的癌变和转移密切相关。然而，CTHRC1在LAC细胞转移中的功能作用及其潜在机制尚未被充分探讨。方法：采用实时荧光定量聚合酶链反应（qRT-PCR）和western blot技术结合生物信息学分析，检测CTHRC1在LAC中的表达水平。采用小干扰RNA和过表达方法研究CTHRC1在LAC细胞中的功能和分子机制。通过生物信息学分析、qRT-PCR、WB、划痕愈合实验、Transwell、检测试剂盒、流式细胞术等方法，研究CTHRC1在LAC细胞中的下游通路和上游调控基因。结合位点通过染色质免疫沉淀（ChIP）和双荧光素酶报告基因实验进行验证。结果：本项目发现CTHRC1在LAC组织和细胞中异常上调。CTHRC1促进LAC细胞的迁移和侵袭。添加奥利司他（脂肪酸合酶抑制剂）后，CTHRC1过表达对LAC细胞迁移的促进作用减弱。在机制上，TF AP-2α (TFAP2A)直接与CTHRC1启动子上游序列结合，促进CTHRC1表达。TFAP2A-CTHRC1轴通过激活脂肪酸代谢诱导LAC细胞迁移。结论：我们的研究结果表明，TFAP2A通过正向调节CTHRC1的表达来激活脂肪酸代谢，从而促进肿瘤细胞的迁移和侵袭。这些发现为LAC的治疗和未来的研究提供了新的见解。

{"title":"TFAP2A activates CTHRC1 to influence the migration of lung adenocarcinoma cells by modulating fatty acid metabolism","authors":"Xiaodong Zheng , Junzheng Zhou , Shiwei Nie , Yuan Chen , Xudong Wei , Jinrui Zhang , Xiaojuan Shen , Weimin Zhang","doi":"10.1016/j.prostaglandins.2024.106941","DOIUrl":"10.1016/j.prostaglandins.2024.106941","url":null,"abstract":"<div><h3>Background</h3><div>Tumor metastasis is the main cause of death in lung adenocarcinoma (LAC) patients. It is known that the collagen triple helix repeats containing 1 (CTHRC1) protein is implicated in tissue remodeling and is tightly linked to the carcinogenesis and metastasis of solid tumors. However, the functional role of CTHRC1 and its potential mechanisms in LAC cell metastasis have not been fully explored.</div></div><div><h3>Methods</h3><div>The expression level of CTHRC1 in LAC was measured by using bioinformatics analysis combined with quantitative real-time polymerase chain reaction (qRT-PCR) and western blot (WB). Small interfering RNA and overexpression methods were employed to investigate the function and molecular mechanisms of CTHRC1 in LAC cells. Through bioinformatics analysis, qRT-PCR, WB, scratch healing assay, Transwell, assay kits, and flow cytometry, the downstream pathways and upstream regulatory genes of CTHRC1 in LAC cells were investigated. The binding sites were verified by using chromatin immunoprecipitation (ChIP) and dual luciferase reporter gene experiments.</div></div><div><h3>Results</h3><div>In this project, CTHRC1 was found to be abnormally upregulated in LAC tissues and cells. CTHRC1 promoted the migration and invasion of LAC cells. The promoting effect of CTHRC1 overexpression on LAC cell migration was weakened after the addition of orlistat (a fatty acid synthase inhibitor). Mechanistically, TF AP-2α (TFAP2A) was directly bound to the upstream sequence of the CTHRC1 promoter and promoted CTHRC1 expression. The TFAP2A-CTHRC1 axis induced the migration of LAC cells by activating fatty acid metabolism.</div></div><div><h3>Conclusion</h3><div>Our results indicated that TFAP2A activates fatty acid metabolism by positively modulating the expression of CTHRC1, thereby facilitating tumor cells’ migration and invasion. These findings provided novel insights into LAC treatment and future research.</div></div>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":"176 ","pages":"Article 106941"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142838424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inflammatory protein levels in asthmatic bronchitis: A study in the Duhok population, Iraq 哮喘支气管炎的炎症蛋白水平：伊拉克Duhok人群的研究。

IF 2.5 3区生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

Prostaglandins & other lipid mediators

Pub Date : 2025-01-01 DOI: 10.1016/j.prostaglandins.2024.106942

Omar A.M. Al-Habib , Hamdia Yousif Issa , Taner Dastan , Sevgi Durna Dastan , Ali A. Ramadhan , Zeliha Selamoglu

Objectives

This study aims to determine the levels of TNF-α, IGF-1, IL-6, and IL-10 protein in blood samples and their potential link to bronchitis-asthma diseases in the Iraq Duhok population, highlighting the prevalence of these long-term inflammatory diseases.

Methods

Sixty blood samples were used and separated into patients (n = 43) and control (n = 17) groups. Serum samples were separated for each individual. Elisa method was used in terms of 4 different proteins investigated in blood samples with the manufacturer’s instruction brand kits.

Results

This study evaluated TNF-α, IGF-1, IL-6, and IL-10 protein levels in blood samples from asthmatic bronchitis patients in Duhok. Although these levels were elevated compared to controls, the differences were not statistically significant.

Conclusion

The differences thought to be related to the bronchitis-asthma diseases could not be demonstrated between the patient and control groups in Iraq Duhok population. Future research should explore larger sample sizes and stratified patient groups to identify potential biomarkers.

研究目的本研究旨在确定血液样本中 TNF-α、IGF-1、IL-6 和 IL-10 蛋白的水平及其与伊拉克杜霍克人口中支气管炎-哮喘疾病的潜在联系，突出这些长期炎症性疾病的发病率：使用了 60 份血液样本，并将其分为患者组（样本数=43）和对照组（样本数=17）。每个人的血清样本均已分离。结果：该研究评估了 TNF-α、TNF-α-1、TNF-α-2、TNF-α-3、TNF-α-4 和 TNF-α-5：本研究评估了杜霍克哮喘性支气管炎患者血液样本中的 TNF-α、IGF-1、IL-6 和 IL-10 蛋白水平。虽然这些水平与对照组相比有所升高，但差异并无统计学意义：结论：认为与支气管炎-哮喘疾病相关的差异在伊拉克杜霍克人群中的患者组和对照组之间未能得到证实。未来的研究应探索更大的样本量和分层患者群体，以确定潜在的生物标志物。

{"title":"Inflammatory protein levels in asthmatic bronchitis: A study in the Duhok population, Iraq","authors":"Omar A.M. Al-Habib , Hamdia Yousif Issa , Taner Dastan , Sevgi Durna Dastan , Ali A. Ramadhan , Zeliha Selamoglu","doi":"10.1016/j.prostaglandins.2024.106942","DOIUrl":"10.1016/j.prostaglandins.2024.106942","url":null,"abstract":"<div><h3>Objectives</h3><div>This study aims to determine the levels of TNF-α, IGF-1, IL-6, and IL-10 protein in blood samples and their potential link to bronchitis-asthma diseases in the Iraq Duhok population, highlighting the prevalence of these long-term inflammatory diseases.</div></div><div><h3>Methods</h3><div>Sixty blood samples were used and separated into patients (n = 43) and control (n = 17) groups. Serum samples were separated for each individual. Elisa method was used in terms of 4 different proteins investigated in blood samples with the manufacturer’s instruction brand kits.</div></div><div><h3>Results</h3><div>This study evaluated TNF-α, IGF-1, IL-6, and IL-10 protein levels in blood samples from asthmatic bronchitis patients in Duhok. Although these levels were elevated compared to controls, the differences were not statistically significant.</div></div><div><h3>Conclusion</h3><div>The differences thought to be related to the bronchitis-asthma diseases could not be demonstrated between the patient and control groups in Iraq Duhok population. Future research should explore larger sample sizes and stratified patient groups to identify potential biomarkers.</div></div>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":"176 ","pages":"Article 106942"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142865532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Innovative approaches to eczema treatment: A review of Fevipiprant and its potential as a new therapeutic agent 湿疹治疗的创新途径：热吡普兰及其作为一种新型治疗剂的潜力综述。

IF 2.5 3区生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

Prostaglandins & other lipid mediators

Pub Date : 2025-01-01 DOI: 10.1016/j.prostaglandins.2024.106946

Rahul Jaiswal , Sageer Ahmad , Supriya Pandey , Asad Ali , Rupali Jaiswal , Reetu Yadav , Reema Yadav , Rabiya Ahsan , Tapasya Dwivedi

Eczema is also known as atopic dermatitis, which goes on to affect the skin as a chronic inflammatory disease. It is associated with a constant feeling of scratchiness, erthyma and disruption of the natural skin barrier. Treatment provided at present may improve some of the symptoms, for instance use of corticosteroids or immunosuppressive agents, however, there is an overwhelming need for better focused and effective methods of treatment with minimal adverse effects. Fevipiprant, a DP2 receptor antagonist, has emerged as a promising agent targeting prostaglandin D2 (PGD2) pathways, which play a crucial role in eczema pathophysiology.

This review examines the mechanism of action, pharmacological profile of Fevipiprant and present studies on preclinical and clinical development of Fevipiprant for treatment of eczema. Additionally, we provide a comparison of Fevipiprant with existing treatment options and evaluate its safety and tolerability. The evaluation gives a reason that targeting in the treatment of eczema by the use of Fevipiprant is able to effectively target the DP2 pathway which is associated with a good safetyl however presenting itself as a new treatment option in the management of eczema. Finally, long-term studies are essential to validate the feasibility, safety, and effectiveness of Fevipiprant compared to existing therapies for eczema. Novartis has taken advantage of this stat for comp… given the scarcity of effective therapies for paediatric atopic dermatitis in Japan. Exploring Fevipiprant from the Efficacy Perspective is also required because it will impact how it will enter clinical practice in therapy of eczema in the future.

湿疹也被称为特应性皮炎，它作为一种慢性炎症性疾病继续影响皮肤。它与持续的瘙痒感、胸腺炎和自然皮肤屏障的破坏有关。目前提供的治疗可能会改善某些症状，例如使用皮质类固醇或免疫抑制剂，但是，迫切需要更有针对性和更有效的治疗方法，将不良反应降到最低。Fevipiprant是一种DP2受体拮抗剂，作为一种有前景的靶向前列腺素D2 （PGD2）通路的药物，在湿疹的病理生理中起着至关重要的作用。本文综述了非维哌兰特的作用机制、药理特征以及非维哌兰特治疗湿疹的临床前和临床研究进展。此外，我们提供了Fevipiprant与现有治疗方案的比较，并评估其安全性和耐受性。该评价表明，使用Fevipiprant靶向治疗湿疹能够有效地靶向DP2通路，具有良好的安全性，同时也为湿疹治疗提供了新的治疗选择。最后，与现有的湿疹治疗方法相比，长期研究对于验证Fevipiprant的可行性、安全性和有效性至关重要。鉴于日本儿科特应性皮炎缺乏有效的治疗方法，诺华利用了这一优势。从疗效角度探索Fevipiprant也很有必要，因为这将影响其未来如何进入临床治疗湿疹的实践。

{"title":"Innovative approaches to eczema treatment: A review of Fevipiprant and its potential as a new therapeutic agent","authors":"Rahul Jaiswal , Sageer Ahmad , Supriya Pandey , Asad Ali , Rupali Jaiswal , Reetu Yadav , Reema Yadav , Rabiya Ahsan , Tapasya Dwivedi","doi":"10.1016/j.prostaglandins.2024.106946","DOIUrl":"10.1016/j.prostaglandins.2024.106946","url":null,"abstract":"<div><div>Eczema is also known as atopic dermatitis, which goes on to affect the skin as a chronic inflammatory disease. It is associated with a constant feeling of scratchiness, erthyma and disruption of the natural skin barrier. Treatment provided at present may improve some of the symptoms, for instance use of corticosteroids or immunosuppressive agents, however, there is an overwhelming need for better focused and effective methods of treatment with minimal adverse effects. Fevipiprant, a DP2 receptor antagonist, has emerged as a promising agent targeting prostaglandin D2 (PGD2) pathways, which play a crucial role in eczema pathophysiology.</div><div>This review examines the mechanism of action, pharmacological profile of Fevipiprant and present studies on preclinical and clinical development of Fevipiprant for treatment of eczema. Additionally, we provide a comparison of Fevipiprant with existing treatment options and evaluate its safety and tolerability. The evaluation gives a reason that targeting in the treatment of eczema by the use of Fevipiprant is able to effectively target the DP2 pathway which is associated with a good safetyl however presenting itself as a new treatment option in the management of eczema. Finally, long-term studies are essential to validate the feasibility, safety, and effectiveness of Fevipiprant compared to existing therapies for eczema. Novartis has taken advantage of this stat for comp… given the scarcity of effective therapies for paediatric atopic dermatitis in Japan. Exploring Fevipiprant from the Efficacy Perspective is also required because it will impact how it will enter clinical practice in therapy of eczema in the future.</div></div>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":"176 ","pages":"Article 106946"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142910432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 2.5 3区生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

Prostaglandins & other lipid mediators

Pub Date : 2025-01-01

引用次数: 0

IF 2.5 3区生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

Prostaglandins & other lipid mediators

Pub Date : 2025-01-01

引用次数: 0

IF 2.5 3区生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

Prostaglandins & other lipid mediators

Pub Date : 2025-01-01

引用次数: 0

首页上一页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Prostaglandins & other lipid mediators

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀